Majority of Youth Overdose Deaths from 2018 to 2022 Were Driven by Fentanyl Alone
NEW YORK, May 20, 2025 /PRNewswire/ -- Fatal drug overdoses among youth aged 15 to 24 in the United States involving synthetic opioids alone—not mixed with other substances—soared by 168 percent over the five-year time period of 2018 to 2022, a new study shows. Published online today in the journal Pediatrics, the work also found that youth overdose rates and drug combinations varied significantly across age, sex and race/ethnicity.
Led by NYU Grossman School of Medicine, the new study is the first, say investigators, to identify which specific combinations of drugs drove synthetic opioid-involved fatal overdoses among young people across sociodemographic groups over time.
Overdoses that involved synthetic opioids alone—predominantly fentanyl—had the highest rates of fatalities when compared to overdoses involving other drug combinations examined by the researchers. This was regardless of age, sex and race/ethnicity.
"Before we looked at the data, we thought we would find that the majority of fatal youth overdoses involved fentanyl combined with other substances, such as prescription opioids or cocaine," said Noa Krawczyk, PhD, assistant professor in the Department of Population Health, and senior author of the study. "Instead, we found the opposite—that most deaths were caused by fentanyl alone. Our analysis sheds light on the changing nature and risks of the drug supply and how they impact key demographic groups. Some may think they are taking one substance but are actually exposed to another."
According to Krawczyk, who is also associate director of the Center for Opioid Epidemiology and Policy at NYU Langone, their findings underscore the need to tailor overdose prevention strategies that include harm reduction services specifically to youth to prevent death and suffering among this under-studied population.
How the Study was Conducted
Analyzing data from the National Center for Health Statistics, the researchers characterized trends in overdose death involving synthetic opioids (predominantly fentanyl) alone, as well as in combination with five common other drugs (benzodiazepines, heroin, prescription opioids, cocaine, and other stimulants) among youth aged 15-24 across age, sex and race/ethnicity over five years (from 2018 to 2022).
The investigators found that during the five-year study period, overdoses involving synthetic opioids alone increased by 168 percent—the highest rates of fatalities compared to those that included a combination of the examined drugs, regardless of age, sex and race/ethnicity.
After deaths due to synthetic opioids/fentanyl alone, the next highest rates of fatal overdoses involved fentanyl combined with cocaine or another stimulant; however, rates differed by age, sex, race/ethnicity and over time. In 2018, White non-Hispanic youth had the highest rates of overdoses involving synthetic opioids/fentanyl alone. By 2022, rates of overdose deaths involving only fentanyl among Black American, American Indian and Alaska Native, and Hispanic youth exceeded White non-Hispanic youth. When it came to the impact of sex and age, fatal overdoses across all groups were highest among males, as well as all youth aged 20 to 24.
According to the research team, understanding the landscape of overdose patterns provides needed context in terms of how to best inform specific public health interventions that can prevent more deaths.
Megan Miller, a research coordinator at the NYU Center for Opioid Epidemiology and Policy and lead author of the study, emphasized that "there are a variety of ways to engage youth and reduce their risk of overdose. Schools, places of employment, homeless shelters, child welfare services, and juvenile justice settings are all possible touchpoints to offer education and harm reduction tools such as naloxone and fentanyl test strips. Our findings highlight the need to tailor these strategies to different youth groups based on the types of drugs they are using to help prevent further overdose deaths."
Limitations to the study findings, according to the investigators, include possible misclassification in mortality coding practices, as well as limited sociodemographic information. For example, youth who identify as LGBTQ+ tend to have a higher risk of overdose, yet that information was not available. Due to small sample sizes, the data did not examine youth who may identify as more than one race or ethnicity.
In addition to Krawczyk and Miller, study co-authors from NYU Grossman School of Medicine include Katherine Wheeler-Martin, MPH, Amanda M. Bunting, PhD, and Magdalena Cerdá, DrPH.
Funding for the study was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number K01DA055758. Dr. Bunting was supported by the National Institute on Drug Abuse under Award Number K01DA053435. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About NYU Langone HealthNYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient Inc. has ranked NYU Langone No. 1 out of 115 comprehensive academic medical centers across the nation for three years in a row, and U.S. News & World Report recently placed nine of its clinical specialties among the top five in the nation. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 320 outpatient locations in the New York area and Florida. With $14.2 billion in revenue this year, the system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise.
Media Inquiries:
Sasha Walek646-501-3873Sasha.walek@nyulangone.org
View original content to download multimedia:https://www.prnewswire.com/news-releases/majority-of-youth-overdose-deaths-from-2018-to-2022-were-driven-by-fentanyl-alone-302459672.html
SOURCE NYU Langone
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
11 hours ago
- Los Angeles Times
Trump told polluters to email him for an exemption. In California, three places have already been approved
Three industrial facilities in California have received exemptions from the U.S. Environmental Protection Agency to emit a carcinogenic chemical after the Trump administration invited large emitters to bypass key provisions of the Clean Air Act by simply sending an email. The EPA in March announced that it would allow large stationary sources of air pollution — that is, sources that aren't vehicles — to apply for an exemption that would enable them to avoid regulations that limit hazardous emissions. The provision in question applies to the regulation of nearly 200 pollutants, including mercury, arsenic, benzene and formaldehyde. The nation's top environmental agency said the exemptions could be granted under the president's authority 'if the technology to implement the standard is not available and it is in the national security interests of the United States to do so.' Environmental groups were outraged by the announcement — dubbing the email offer as an 'inbox from hell.' As of publication, at least 340 facilities nationwide have received or applied for exemptions from the EPA, including 87 in Texas, 51 in Louisiana and 18 in Pennsylvania, according to a tracker created by the nonprofit Environmental Defense Fund. So far, three facilities in California have applied for and received approval. All three belong to Sterigenics, a company that provides industrial sterilization technology for medical devices and other commercial products at two locations in Los Angeles and one in San Bernardino County. The rule from which they are seeking relief applies to a chemical known as ethylene oxide, or EtO, which is commonly used to sterilize medical devices that can't be cleaned using steam or radiation. An estimated 50% of sterile medical devices in the U.S. are treated with EtO. The colorless gas is also used to make chemicals found in products such as antifreeze, detergents, plastics and adhesives. Yet the EPA's own website notes that short-term exposure to EtO by inhalation can cause adverse health effects including headaches, dizziness, nausea, fatigue, respiratory irritation, gastrointestinal distress and vomiting. Long-term exposure is even worse, with the EPA website noting that 'EtO is a human carcinogen. It causes cancer in humans.' Specifically, chronic exposure to ethylene oxide over many years increases the risk of cancers of the white blood cells, such as non-Hodgkin lymphoma, as well as breast cancer, according to the EPA. Children are particularly susceptible to its health risks. Granting exemptions for such emissions is 'something we should all be concerned about,' said Will Barrett, assistant vice president for nationwide clean air policy at the American Lung Assn. 'The public counts on these types of protections to ensure that their families are limiting their exposures to cancer-causing and other health risk-inducing pollutants,' Barrett said. 'And to the extent that these exemption requests are allowed to undermine that, or to delay and continue the pollution that people are being exposed to — that can have deadly consequences.' The Biden administration took steps to strengthen regulations for ethylene oxide under its amended air toxics standards in 2024, designed to reduce the amount of EtO released from commercial sterilizers by 90% and lessen the hazards for nearby communities. The Trump administration instead argued those regulations place 'severe burdens on commercial sterilization facilities,' and risk making sterile medical devices unavailable to patients who need them. 'The continued utilization of ethylene oxide by commercial sterilization facilities is essential to ensuring that our Nation provides its sick and injured with the best outcomes possible — an objective that is at the forefront of the Federal Government's responsibility to the American people,' Trump wrote in a July executive order. Trump in that same order listed nearly 40 facilities receiving exemptions from EtO compliance deadlines for two years, including the Southern California plants belonging to Sterigenics, one in Ontario, and two across the street from each other in Vernon. In a statement, a Sterigenics spokesperson said the company 'remains committed to operating safe facilities that protect patients, employees and communities.' 'The company has proactively implemented additional enhancements to further reduce already negligible levels of EtO emissions,' the statement said. 'This extension to the timeline will allow Sterigenics to continue to make thoughtful, proactive investments and focus resources on ensuring stable, reliable compliance.' According to public data, the two Sterigenics plants in Vernon released a combined 78 lbs of ethylene oxide emissions in 2024, while the one in Ontario released 612 lbs. By comparison, one of the largest ethylene oxide emitters in the country, the Union Carbide plant in Louisiana, emitted 6,894 lbs. in 2024. The federal government also granted that facility an exemption. This is not the first time Sterigenics has faced scrutiny. In 2022, the South Coast Air Quality Management District issued violation notices for improperly handling ethylene oxide to Sterigenics and another company called Parter Medical Products in Carson for improper handling of ethylene oxide. Biden's standards are set to go into effect in mid-2026. The Trump administration has said one reason it is issuing these exemptions is that the technology to implement these stricter standards 'does not exist.' But the Biden administration would not have finalized the rules if such technology were not available, according to Ellen Robo, senior manager of clean air policy and analytics at the Environmental Defense Fund, who helped create the tracker. 'The standards that are now being ignored by these exemptions were carefully considered,' Robo said. 'And with this arbitrary designation, they are being allowed to pollute in these communities with very little notice.' Robo said at least 10 more sterilization plants in California are governed by the ethylene oxide standards, and it's likely that they have also applied for an exemption. They are located in Los Angeles, Orange, San Diego, Riverside, Sacramento and Marin counties. Thinking nationally, this is just one of eight rules for which the EPA has recently offered exemptions via email. The others include rules governing mercury and air toxics; polymers and resins; rubber tires; copper smelting; and coal power, among others. 'These are things that cause cancer, cause developmental delays in children and babies,' Robo said. 'These are many of the most toxic pollutants.' The EPA's exemption template asked applicants to explain why they can't currently meet the emissions reduction goals and why an extension is in the national security interests of the country. The EPA said an email alone doesn't guarantee an exemption but that the president 'will make a decision on the merits.' The two-year exemptions can potentially be renewed, the agency said. While California so far has been granted fewer exemptions than some other states, it also has consistently ranked as one of the worst states for air quality in the nation, said Barrett of the American Lung Assn. The group's most recent annual 'State of the Air' report ranked San Bernardino as the nation's most polluted county for ozone and particle pollution, while Los Angeles has been ranked the nation's smoggiest city 25 of the last 26 years. 'For the millions and millions of people — and hundreds of thousands of children — living with asthma and other respiratory illnesses that people are dealing with on a daily basis, any erosion of the clean air protections under the Clean Air Act is a real step backward and a rejection of decades of peer-reviewed scientific literature about the harms of air pollution,' Barrett said.
Associated Press
18 hours ago
- Associated Press
DermRays Celebrates 13 Years of Skincare Innovation with Exclusive Anniversary Sale and Groundbreaking 1450nm Laser Device for 2026
PLEASANTON, Calif., Aug. 15, 2025 /PRNewswire/ -- DermRays, a pioneer in at-home skincare technology, marks its 13th anniversary with a celebration of its best-selling devices and a sneak peek at its upcoming 1450nm laser skincare tool, slated for launch in early 2026. This milestone underscores the brands commitment to merging cutting-edge science with accessible beauty solutions. Anniversary Spotlight: Award-Winning Skincare Heroes To thank customers for their trust, DermRays is offering limited-time discounts on three transformative devices designed to rejuvenate skin at home: 1. DermRays Revive The first and only at-home laser with ultra-high energy for collagen regeneration. Ideal for reducing fine lines and boosting collagen, its a clinic-grade tool for a fraction of the cost. Revive uses cutting-edge 1064nm laser technology, the same as that employed by leading salon brands. 2. FusionGlow Multi-Functional Microcurrent Toning Device Beyond Microcurrent: 5 Skincare Technologies You Need. Comprehensive Skin Revitalization: Brighten, Hydrate, Rejuvenate. Achieve radiant, firm skin in 14 days with clinically visible results backed by SGS. 3. LED Light Therapy Silicone Mask Your daily skincare companion: blue, red, infrared, and mixed light for every need. Only 15 minutes a day for youthful and radiant skin. 'For 13 years, we've empowered users to take control of their skincare routines with safe, effective technology,' says Dr. Yang Lin, Brand Director at DermRays. 'Our anniversary sale is a tribute to our community-and just the beginning of whats next.' 4. The Future: 1450nm Laser Skincare Device DermRays is set to revolutionize at-home treatments again with its 1450nm laser device (expected Q1 2026). It stimulates natural collagen production to smooth fine lines, restore firmness, and reverse signs of aging. This tool will expand the brands professional-grade offerings, bridging the gap between spa treatments and home care. Join the Celebration From August 1-31, 2025, enjoy exclusive anniversary bundles and discounts on DermRays bestselling devices. Follow @DermRays on social media for giveaways and live demos. About DermRays Since 2011, DermRays has combined dermatological research with accessible technology, offering FDA/CE/UKCA-cleared, non-invasive devices for radiant, youthful skin at home. View original content to download multimedia: SOURCE DermRays
New York Post
a day ago
- New York Post
Three babies die amid ‘concerning rise' of syphilis in New York — what to know about the dangerous disease
At least three babies have died of presumed congenital syphilis in New York state this year, prompting health officials to warn about the risks of the preventable infection. A pregnant woman can pass syphilis, a sexually transmitted infection, to her fetus. Left untreated, congenital syphilis can lead to miscarriage, premature birth, skeletal abnormalities, neurological problems, developmental delays, stillbirth or infant death shortly after birth. 3 There's been a 'concerning rise' in congenital syphilis cases in New York this year, state health officials said this week. HENADZY – Advertisement 'Detecting syphilis early in pregnancy with a simple blood test is important to ensure rapid diagnosis and treatment, so you have a healthy baby,' State Health Commissioner Dr. James McDonald said in a statement this week. New York has reported 21 cases of congenital syphilis in counties outside of NYC this year. Authorities did not disclose where the three infant deaths happened, except that they weren't in the city. There were 36 cases in the region outside of NYC last year, including five stillbirths and one infant death. Eight infant deaths presumptively linked to syphilis were recorded in the area between 2019 and 2023. Advertisement 'The highest rates we're seeing are in Native Americans, American Indians, Alaska Natives, Hispanic populations and black populations,' Kristin Wall, an associate professor of epidemiology at Emory University's Rollins School of Public Health, told ABC News about national congenital syphilis trends. 'And I think it's really important to think about access to care barriers as one of the big reasons that we're seeing these increasing rates in certain populations.' 3 A newborn in 1963 displays signs of congenital syphilis. Getty Images Unsurprisingly, there has been a 'concerning' rise in infectious syphilis cases among female New York residents, contributing to a nationwide surge. Advertisement Researchers have speculated that the increase could be due to decreased condom use, a disruption in healthcare routines because of the COVID-19 pandemic, inadequate sex education and disparities in access to testing and screening services. New York officials observed that substance use and hepatitis C were notable threads throughout congenital syphilis cases in the state. Last year, New York implemented a requirement for syphilis screening during the third trimester. Advertisement Pregnant women must now be tested for syphilis at their first prenatal appointment, in their third trimester (between weeks 28 and 32) and at delivery. Penicillin is the recommended treatment for syphilis, though some people may be allergic. In those cases, desensitization may be necessary. Unfortunately, there's been a nationwide penicillin shortage for months, compounding syphilis concerns. 3 A syphilis rash often appears as reddish-brown spots on the palms of the hands and soles of the feet. Stock Media Labs – Syphilis is spread by vaginal, anal or oral sex. Symptoms typically emerge 10 to 90 days after exposure, starting with a painless sore that appears at the site where the bacterium Treponema pallidum entered the body. The sore can heal on its own in three to six weeks, even as the infection persists. In the next stage of infection, symptoms can include a rash, fever, fatigue, sore throat, swollen lymph nodes and hair loss. Advertisement Syphilis is typically diagnosed with a blood test. New York's health department reminded residents that they have access to at-home testing options for sexually transmitted infections. If not addressed, syphilis can devastate the brain, heart and nervous system, leading to blindness, paralysis and even death.
